New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News For MRK;PFE;GSK;JNJ;BMY;NVS;SHPG;ABT;CELG;SNY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
<< 1 | 2 | 3 | 4 | 5 | 6 | 7 | all recent news | >>
May 5, 2015
10:29 EDTMRKGilead receives negative claim construction ruling, Markman Advisors says
Subscribe for More Information
09:31 EDTGSKGlaxoSmithKline, partners make EU submission for gene therapy to treat ADA-SCID
Subscribe for More Information
09:07 EDTBMYUBS healthcare and biotech analysts hold an analyst/industry conference call
Subscribe for More Information
07:57 EDTCELGDeutsche sees AbbVie, BioMarin outperforming near-term
Deutsche Bank analyst Robyn Karnauskas expects shares of AbbVie (ABBV) and BioMarin (BMRN) to outperform in the near-term following recent weakness in the biotech sector. On AbbVie, Karnauskas thinks data readouts in 2015 could add $15-$25 per share over time. For BioMarin, the analyst thinks only three of the five pipeline readouts need to work in 2015. The company's takeout valuation could be up to $217 per share if data for BMN-111 for Achondroplasia, Drisapsrsen for Duchenne muscular dystrophy and BMN 270 for hemophilia are positive, Karnauskas believes. The analyst also recommends buying Celgene (CELG) and Alexion (ALXN) on any weakness for upside in the second half of 2015.
May 4, 2015
09:35 EDTPFEActive equity options trading on open
Subscribe for More Information
08:52 EDTSHPGShire deserves premium valuation, says Susquehanna
Susquehanna said Shire deserves its premium valuation as it continues to deliver solid performance from marketed products while investing for longer-term growth from its pipeline. Susquehanna reiterated its Positive rating and $290 price target on Shire shares.
07:35 EDTPFE, JNJ, BMY, NVSNewYorkBio to hold a conference
Subscribe for More Information
07:26 EDTBMY, SHPG, MRK, PFEWorldwide Business Research to hold a conference
BioNetwork East 2015 Partnering Conference is being held in Miami on May 4-6.
07:23 EDTBMYAmerican Association of Neurological Surgeons to hold annual meeting
Subscribe for More Information
07:17 EDTABTAbbott has a conference call hosted by JPMorgan
JPMorgan Analyst Weinstein will host a conference call with CEO Miles White on May 8 at 11 am.
07:12 EDTMRKAmerican Congress of Obstetrics and Gynecology
2015 ACOG Annual Clinical & Scientific Meeting is being held in San Francisco on May 2-6.
07:04 EDTMRKTrevena names Carrie Bourdow as Chief Commercial Officer
Subscribe for More Information
07:02 EDTSHPGShire and the Foundation Fighting Blindness announce agreement
Shire and the Foundation Fighting Blindness announced a new agreement focused on furthering research for a novel treatment for autosomal dominant retinitis pigmentosa, or adRP, a rare genetic disease that usually first occurs in late childhood or adolescence and is followed by the progressive loss of peripheral vision. There are no currently approved treatment options for adRP. As part of the agreement, the Foundation Fighting Blindness and its research partners will provide Shire with expert knowledge and scientific background regarding adRP, as well as pertinent clinical information that could be useful in the development of a drug to treat adRP. Shire is compensating the Foundation Fighting Blindness for its considerable expertise in early-stage drug discovery and development, as well as making available it significant expertise and experience with the submission of investigational new drug applications.
05:54 EDTMRKMerck KGaA wants to be more assertive on brand name, Financial Times says
Subscribe for More Information
May 3, 2015
18:11 EDTJNJ, GSKSiemens investigated by Chinese regulator last year, Reuters says
Subscribe for More Information
16:04 EDTCELGAcceleron reports luspatercept data, says increases hemoglobin levels
Subscribe for More Information
May 1, 2015
16:49 EDTJNJJ&J says Costco filed complaint against Vision Care unit
Subscribe for More Information
16:31 EDTMRKMarket ends week lower as Apple, Twitter pull back after earnings
Subscribe for More Information
16:28 EDTCELGAgios Pharmaceuticals enters license agreement with Celgene
Subscribe for More Information
16:02 EDTPFEOn The Fly: Morning Wrap-Up for May 1
Subscribe for More Information
15:14 EDTNVSExpress Scripts in settlement pact related to alleged Novartis kickbacks
Accredo Health, a wholly-owned subsidiary of Express Scripts (ESRX), entered a settlement and dismissal agreement with United States Attorney for the Southern District of New York, Preet Bharara, related to Accredo's alleged involvement in Novartis's (NVS) alleged participation in a kickback scheme involving Exjade, according to a court filing. In settlement of the United States' claims against Accredo in this action, Accredo shall pay to the United States a sum just over $45M, according to the court filing. A recent filing with the SEC noted that a total of $60M was set aside by Express Scripts to resolve the allegations with the federal government and all 50 states and a company spokesman confirmed the settlement involves $60M, according to The Wall Street Journal. Reference Link
12:26 EDTCELG, SHPGBiogen patent challenged by Kyle Bass
The Coalition For Affordable Drugs, a group linked to Hayman Capital's Kyle Bass, has requested an Inter Partes Review of Claims 1-20 of US patent 8,399,514 held by Biogen (BIIB), according to a USPTO filing. The patent is related to the company's multiple sclerosis drug. BACKGROUND: Previously, the same coalition requested an Inter Partes Review of patents held by Celgene (CELG), Pharmacyclics (PCYC), Acorda Therapeutics (ACOR), Shire (SHPG) and Jazz Pharmaceuticals (JAZZ). PRICE ACTION: Shares of Biogen are up 3% to $385.29 in afternoon trading.
10:20 EDTSHPGShire management to meet with Jefferies
Subscribe for More Information
08:44 EDTSHPGShire price target raised to $298 from $262 at SunTrust
Subscribe for More Information
08:04 EDTCELGCelgene weakness creates great entry point, says Bernstein
Subscribe for More Information
07:43 EDTCELG, GSK, PFE, NVS, SNY, MRK, JNJ, BMYExpensive drugs drove over 25% of 2013 Medicare drug spending, WSJ says
Subscribe for More Information
07:36 EDTCELGCelgene says analysis of Revlimid in non-del-5Q-MDS showed improved QOL measures
Subscribe for More Information
April 30, 2015
16:59 EDTGSKGlaxoSmithKline, Theravance announce FDA approval of Breo Ellipta
Subscribe for More Information
16:01 EDTCELGOptions Update; April 30, 2015
iPath S&P 500 VIX Short-Term Futures up 60c to 21.84. Option volume leaders: AAPL TSLA TWTR GILD FB AMZN CELG VZ KMI according to Track Data.
15:20 EDTGSKGlaxo says FDA issued CRL on use of Breo Ellipta in patients aged 12-17
Subscribe for More Information
15:17 EDTGSKGlaxoSmithKline says FDA approves BREO ELLIPTA for adults with asthma
GlaxoSmithKline (GSK) and Theravance (THRX) announced that the FDA has approved BREO ELLIPTA for the once-daily treatment of asthma in patients aged 18 years and older. Breo Ellipta is not indicated for the relief of acute bronchospasm. Breo is a fixed-dose combination of the inhaled corticosteroid fluticasone furoate and the long-acting beta2-agonist vilanterol. Two strengths, 100/25mcg and 200/25mcg, have been approved in the US for use in asthma, administered once-daily using the Ellipta dry powder inhaler.
10:46 EDTCELGLeerink biotech analyst holds an analyst/industry conference call
Biotech Analyst Liang, along with Dr. Alan List an MDS Specialist, provide an update on the myelodysplastic syndrome pipeline on an Analyst/Industry conference call to be held on May 5 at 2:30 pm.
10:34 EDTPFEPfizer 'mystery bidder' for Swedish Orphan Biovitrum, Reuters says
Subscribe for More Information
09:36 EDTBMYBayer says Xarelto not losing market share to Eliquis, Reuters reports
Bayer (BAYRY) says Xarelto is not losing its U.S. market share to Bristol-Myers' (BMY) Eliquis, reports Reuters. In a conference call, Bayer said that Eliquis was taking business from warfarin and other drugs, but not from Xarelto. Reference Link
09:18 EDTCELGOn The Fly: Pre-market Movers.
UP AFTER EARNINGS: Glu Mobile (GLUU), up 28.2% after reporting first quarter results and deals with Tencent and Britney Spears... Civeo (CVEO), up 3.05... TASER (TASR), up 9.6%... Virgin America (VA), up 2.7%... Noble Corp (NE), up 1.8%... Statoil (STO), up 2.8%... Alpha Natural (ANR), up 3.6%... Exxon Mobil (XOM), up 1.4%... Phillips 66 (PSX), up 1.2%... NXP Semiconductors (NXPI), up 2.4%. ALSO HIGHER: Clicksoftware (CKSW), up 27.8% after being acquired by Francisco Partners... JetBlue (JBLU), up 1.4% after being upgraded to Outperform from Neutral at Credit Suisse... WuXi PharmaTech (WX), up 16.5% after receiving going private proposal. DOWN AFTER EARNINGS: Yelp (YELP), down 17.1%... Celgene (CELG), down 2.4%... STMicroelectronics (STM), down 11.4%... Harman International (HAR), down 9%... Potash (POT), down 2.4%... Generac (GNRC), down 7%... Nokia (NOK), down 8.7%... Baidu (BIDU), down 2.6%. ALSO LOWER: Inovio Pharmaceuticals (INO), down 18.1% after 9.5M share Spot Secondary priced at $8.00... Miller Energy (MILL), down 9% after receiving 'Wells Notice'... Scorpio Tankers (STNG), down 7.5% after 15M share Spot Secondary priced at $9.30... Advaxis (ADXS), down 6% after 2.8M share Spot Secondary priced at $19.00.
09:14 EDTCELGOn The Fly: Pre-market Movers.
Subscribe for More Information
09:05 EDTCELGCelgene receives orphan status for lymphoma treatment
The FDA granted Celgene for its treatment of extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue, Revlimid.
09:04 EDTCELGCelgene receives orphan status for lymphoma treatment
07:44 EDTCELGAcceleron, Celgene select Luspatercept to advance to Phase 3
Acceleron Pharma (XLRN) announced that Acceleron and its collaboration partner, Celgene Corporation (CELG), plan to initiate a Phase 3 program with luspatercept in myelodysplastic syndromes and beta-thalassemia by year-end 2015. The companies will continue to develop sotatercept for patients with chronic kidney disease. Preliminary data from the ongoing phase 2 clinical trial of luspatercept in patients with lower risk MDS will be presented by Uwe Platzbecker, M.D., University Hospital in Dresden, Germany, in the oral session “Best of Clinical Trials II” at the MDS Foundation 13th International Symposium on Myelodysplastic Syndromes on Saturday May 2, 2015, at 10:30 AM at the Washington Marriott Wardman Park Hotel in Washington, D.C.
07:32 EDTCELGCelgene reaffirms FY15 adjusted EPs view $4.60-$4.75, consensus $4.81
Reaffirms total net product sales $9B-$9.5B, consensus $9.32B. REVLIMID® net sales are expected to be in the range of $5,600 million to $5,700 million ABRAXANE® net sales are expected to be in the range of $1,000 million to $1,250 million
07:32 EDTCELGCelgene reports Q1 adjusted EPS $1.07, consensus $1.06
Subscribe for More Information
07:21 EDTGSKFDA PDUFA Date for Theravance BREO ELLIPTA is April 30, 2015
07:09 EDTSHPGShire reaffirms 2015 EPS growth outlook of mid-single digits
Shire said, "We've made a strong start to 2015, and remain confident in delivering Non GAAP diluted earnings per ADS growth in the mid-single digits in 2015. On a Constant Exchange Rate basis we continue to expect product sales growth in the mid-to-high single digits. When excluding INTUNIV, we anticipate low double digit product sales growth on a CER basis. Based on current exchange rates we anticipate low-to-mid single digit product sales growth in 2015, as we expect growth to be held back three to four percentage points by foreign exchange headwinds which particularly impact ELAPRASE, REPLAGAL and VPRIV sales. We expect to see a lower rate of product sales growth through the remainder of 2015 than we've delivered in the first quarter, principally due to stronger comparatives. Royalties and other revenues are expected to increase by 30-40% in 2015, as we include NPS's royalty streams for the first time. Our Non GAAP gross margin is expected to be in line with 2014."
07:08 EDTSHPGShire reports Q1 adjysted EPS $2.84, consensus $2.61
Subscribe for More Information
07:06 EDTSHPGShire appoints Jeff Poulton as CFO
Subscribe for More Information
05:41 EDTSNYSanofi sees FY15 business EPS to be stable to slightly growing vs. 2014
The positive currency impact on 2015 full-year business EPS is estimated to be approximately 12%, under the assumption that exchange rates remain stable in the following three quarters at the average rates of March 2015.
05:40 EDTSNYSanofi reports Q1 business EPS 1.32 vs. EUR 1.17 last year
Subscribe for More Information
April 29, 2015
17:09 EDTBMYBristol-Myers announces FDA acceptance for sBLA for Opdivo
Subscribe for More Information
17:00 EDTJNJJohnson & Johnson announces further patent action related to Remicade
Subscribe for More Information
15:00 EDTCELGNotable companies reporting before tomorrow's open
Subscribe for More Information
12:25 EDTJNJPerrigo rumored to possibly draw interest beyond Mylan bid, Bloomberg says
Subscribe for More Information
10:39 EDTPFE, BMYCiti analyst says outlook still strong for big pharma
Subscribe for More Information
10:00 EDTSHPGOn The Fly: Analyst Initiation Summary
Subscribe for More Information
10:00 EDTPFEOn The Fly: Analyst Downgrade Summary
Today's noteworthy downgrades include: American Capital Agency (AGNC) downgraded at UBS... American Public Education (APEI) downgraded to Hold from Buy at Deutsche Bank... Annaly Capital (NLY) downgraded at UBS... C.H. Robinson (CHRW) downgraded to Neutral from Buy at BofA/Merrill... Church & Dwight (CHD) downgraded to Perform from Outperform at Oppenheimer... Cobalt (CIE) downgraded to Hold from Accumulate at Tudor Pickering... Compass Minerals (CMP) downgraded to Neutral from Overweight at JPMorgan... Corning (GLW) downgraded to Sell from Underperform at CLSA... Corporate Office Properties (OFC) downgraded at Stifel... Entergy (ETR) downgraded to Market Perform from Outperform at BMO Capital... First Interstate (FIBK) downgraded to Market Perform from Outperform at Wells Fargo... German American Bancorp (GABC) downgraded to Market Perform at Keefe Bruyette... IGI Laboratories (IG) downgraded to Market Perform from Outperform at Avondale... Lumber Liquidators (LL) downgraded at Longbow... Marvell (MRVL) downgraded at JMP Securities... National Oilwell (NOV) downgraded to Underweight from Equal Weight at Morgan Stanley... Oceaneering (OII) downgraded to Neutral from Buy at Sterne Agee CRT... OpenText (OTEX) downgraded to Sector Performer from Outperformer at CIBC... Parker-Hannifin (PH) downgraded on macro headwinds at Stifel... Pfizer (PFE) downgraded to Neutral from Buy at Citigroup... Procter & Gamble (PG) downgraded to Hold from Buy at Societe Generale... RTI International (RTI) downgraded to Market Perform from Outperform at FBR Capital... Ryder (R) downgraded to Neutral from Buy at Goldman... Stratasys (SSYS) downgraded to Neutral from Buy at Goldman... Targa Resources (TRGP) downgraded to Accumulate from Buy at Global Hunter... Total System (TSS) downgraded to Market Perform from Outperform at Wells Fargo... Twitter (TWTR) downgraded to Equal Weight from Overweight at Barclays... Wynn Resorts (WYNN) downgraded to Neutral at Susquehanna.
07:16 EDTCELGAgios Pharmaceuticals plans to advance AG-881 to clinical development
Subscribe for More Information
06:26 EDTBMYBristol-Myers price target raised to $80 from $60 at Citigroup
Citigroup raised its price target for Bristol-Myers to $80 while reiterating its positive on the Pharmaceuticals sector. Citi says it remains positive on the sector despite three years of outperformance. The firm believes biosimilars and transformative efficacy should facilitate "continued reimbursement for novel premium priced therapies." It keeps a Buy rating on Bristol-Myers.
06:16 EDTPFE, BMYPfizer downgraded to Neutral from Buy at Citigroup
Citigroup analyst Andrew Baum downgraded Pfizer (PFE) to Neutral citing the stock's "strong" relative outperformance this year. Buam prefers prefer Eli Lilly (LLY), which he upgraded this morning to Buy, and Bristol-Myers (BMY) among large-cap U.S. Pharmaceuticals. He keeps a $37 price target for Pfizer shares.
06:05 EDTBMYBristol-Myers reports positive results in Hepatitis C candidate daclatasvir
Subscribe for More Information
05:33 EDTSHPGShire initiated with an Outperform at Exane BNP Paribas
Subscribe for More Information
April 28, 2015
17:00 EDTMRKOn The Fly: Top stock stories for Tuesday
Subscribe for More Information
16:00 EDTMRKOptions Update; April 28, 2015
iPath S&P 500 VIX Short-Term Futures down 68c to 20.77. Option volume leaders: AAPL TSLA TWTR YPF AMZN X PBR MRK JBLU ABX according to Track Data.
12:30 EDTBMY, MRK, PFEOn The Fly: Top stock stories at midday
Stocks on Wall Street were higher at midday after crossing back and forth across the flat line during morning trading, much like Apple (AAPL) shares, which were searching for direction despite the company's report last night having topped expectations on several measures, including revenue, profits, iPhone unit sales and capital return plans. ECONOMIC EVENTS: In the U.S., the Case Shiller 20-city home price index rebounded 0.93% on a seasonally adjusted basis in February, versus expectations for it to be up 0.7% on a month-over-month basis. The Conference Board's consumer confidence index dropped 6.2 points to 95.2 in April, versus expectations for it to have risen to 102.2. The Richmond Fed manufacturing index rose to -3 in April, versus expectations for a reading of -2. COMPANY NEWS: Shares of Apple were little changed near noon after the company last night reported March quarter earnings and sales well above expectations and boosted its shares buyback program to $140B from $90B and quarterly dividend by 11% to 52c. FBR Capital called the quarter “Picasso-like,” while Brian White at Cantor Fitzgerald upped his price target on shares to $195. Less sanguine are analysts at Pacific Crest, Maxim and Deutsche Bank. Noted investor Carl Icahn said afterward that Apple is "still undervalued and misunderstood" and promised to put out another in-depth report on the company within two weeks... IBM (IBM) approved an 18% increase in its quarterly dividend to $1.30 per common share. MAJOR MOVERS: Among the notable gainers was Dow member Merck (MRK), which advanced 5% after its Q1 sales and EPS beat expectations. Two other big name, big revenue drugmakers slid after their earnings reports, as Bristol-Myers (BMY) declined 1% and Pfizer (PFE) fell 0.5%. Also lower following its earnings report was The Container Store (TCS), which declined about 16% after its results and outlook missed expectations. INDEXES: Near midday, the Dow was up 49.61, or 0.28%, to 18,087.58, the Nasdaq was up 9.87, or 0.2%, to 5,070.12, and the S&P 500 was up 3.98, or 0.19%, to 2,112.90.
10:00 EDTMRKMerck trades sharply higher after results, levels to watch
The stock is trading up over 5% to $60.17 following results. At that price the only resistance level of significance is at the 52-week high at $63.62. Support is at $59.73, the session low.
09:36 EDTMRKActive equity options trading on open
Subscribe for More Information
08:46 EDTMRK, BMYOn The Fly: Pre-market Movers
Subscribe for More Information
08:27 EDTMRKMerck HCV results appear inferior, says Bernstein
Subscribe for More Information
07:59 EDTMRKMerck HCV data supports NDA filing, says SunTrust
SunTrust believes that Merck's C-EDGE & C-SURFER efficacy data at EASL indicates that the company's HCV treatment is competitive with Gilead's (GILD) single pill dose and superior to AbbVie's (ABBV) Viekira Pak. The firm says the data supports Merck's imminent NDA filing with breakthrough designation, potentially enabling a 2H15 launch. It keeps a $72 price target and Buy rating on the shares.
07:43 EDTABTMead Johnson pushing for changes to WIC program, WSJ reports
The law authorizing the $6B per year WIC program providing food vouchers to women who are pregnant or have young children is up for renewal this year and formula makers, led by top U.S. maker Mead Johnson (MJN), are pushing for change, said The Wall Street Journal. Growth in the program has made it a money-losing venture for baby formula makers who essentially make no profit off formula sold to states as part of the program and Mead Johnson is pushing for changing eligibility requirements, thereby limiting or even shrinking the pool of recipients, the report noted. Other U.S. infant formula makers include Abbott (ABT) and Nestle (NSRGY). Reference Link
07:33 EDTPFEHospira will not provide annual projections given merger agreement with Pfizer
07:33 EDTPFEHospira expects merger agreement with Pfizer to be completed in 2H15
Subscribe for More Information
07:32 EDTBMYBristol-Myers narrows FY15 adjusted EPS view to $1.55-$1.70 from $1.60-$1.70
Consensus $1.72.
07:31 EDTBMYBristol-Myers reports Q1 EPS 71c, consensus 50c
Reports Q1 revenue $4.04B, consensus $3.8B.
07:12 EDTPFEPfizer lowers FY15 adjusted EPS view to $1.95-$2.05 from $2.00-$2.10
Consensus $2.07. Lowers FY15 revenue guidance to $44B-$46B from $44.5B-$46.5B, consensus $45.94B.
07:09 EDTPFEPfizer reports Q1 adjusted EPS 51c, consensus 49c
Subscribe for More Information
07:03 EDTMRKMerck sees FY15 EPS $3.35-$3.48, consensus $3.37
Sees FY15 revenue $38.3B-$39.8B, consensus $39.2B.
07:02 EDTMRKMerck reports Q1 EPS 85c, consensus 74c
Subscribe for More Information
05:53 EDTCELGStocks with implied volatility movement; AMGN CELG
Subscribe for More Information
05:30 EDTSNYGenzyme says FDA grants fast track designation for development of GZ/SAR402671
Genzyme, a Sanofi company, announced that the FDA has granted Fast Track designation for the development of GZ/SAR402671, a new investigational oral substrate reduction therapy for the treatment of Fabry disease. FDA’s Fast Track Drug Development Program is designed to facilitate frequent interactions with the FDA review team to expedite the clinical development and review of a New Drug Application, or NDA, for medicines with the potential to treat serious or life-threatening conditions and address unmet medical needs for such disease or conditions. It also provides the opportunity to submit sections of an NDA on a rolling basis before a sponsor submits the complete application. Genzyme is currently enrolling patients in its Phase 2a trial of GZ/SAR402671, and plans to enroll nine treatment-naïve male adult patients with Fabry disease in this international, multicenter study.
April 27, 2015
18:56 EDTMRKOn The Fly: After Hours Movers
Subscribe for More Information
18:32 EDTMRKMerck announces publication of pivotal data from Zerbaxa Phase 3 clinical study
Subscribe for More Information
17:13 EDTMRKMerck announces Januvia study achieved primary endpoint
Merck announced that the trial evaluating cardiovascular outcomes with Sitagliptin, or TECOS, of Merck's DPP-4 inhibitor, Januvia, or sitagliptin, achieved its primary endpoint of non-inferiority for the composite cardiovascular endpoint. Among secondary endpoints, there was no increase in hospitalization for heart failure in the sitagliptin group versus placebo. The complete results of TECOS will be presented on June 8 at the Scientific Sessions of the American Diabetes Association. TECOS was an event-driven trial conducted in adults with type 2 diabetes and a history of cardiovascular disease. The study was designed to assess the CV safety of long-term treatment with Januvia as part of usual diabetes care compared with usual care without Januvia. The primary endpoint was the composite of time to the first of any of the following confirmed events: cardiovascular-related death, nonfatal myocardial infarction, nonfatal stroke, or unstable angina requiring hospitalization. TECOS enrolled 14,724 participants from 38 countries between December 2008 and July 2012. The median patient follow-up was approximately three years.
15:04 EDTBMY, MRK, PFENotable companies reporting before tomorrow's open
Subscribe for More Information
14:41 EDTPFEEarnings Watch: Pfizer up over 6% since its last earnings report
Subscribe for More Information
13:43 EDTMRKEarnings Watch: Merck shares lower by about 5.6% since last earnings report
Subscribe for More Information
12:47 EDTPFEPfizer technical comments before earnings
Subscribe for More Information
10:30 EDTNVSNovartis says Phase III Arzerra study met primary endpoint
Subscribe for More Information
10:04 EDTGSKHigh option volume stocks
Subscribe for More Information
09:37 EDTMRKBarclays healthcare analysts hold an analyst/industry conference call
Subscribe for More Information
09:03 EDTPFEChina Jo-Jo Drugstore signs incentive agreement with Pfizer subsidiary
China Jo-Jo Drugstores (CJJD) announced its subsidiary, Hangzhou Jiuzhou Grand Pharmacy Chain, has signed a new sales incentive agreement with Wyeth Pharmaceutical, a wholly owned subsidiary in China of Pfizer (PFE). The Agreement illustrated specific approaches and conditions of Jiuzhou Pharmacy's collaboration with Wyeth, including sales targets, promotional incentive to consumers, products and pricing methods. In return, Wyeth will fully support Jiuzhou Pharmacy with priority delivery, favorable purchase prices and promotional activities.
08:46 EDTGSKAgenus data positive, says JMP Securities
Subscribe for More Information
08:41 EDTGSK, PFETelegraph discusses potential takeover of GSK by Pfizer
Subscribe for More Information
08:19 EDTBMYBristol-Myers announces ALLY-1 trial met primary endpoints
Subscribe for More Information
07:31 EDTCELGCelgene to acquire Quanticel Pharmaceuticals for $100M in cash
Subscribe for More Information
06:19 EDTSNY, BMY, MRK, GSK, JNJ, NVS, PFEPharmceutical companies buy drugs and raises prices, WSJ reports
Subscribe for More Information
April 26, 2015
12:50 EDTCELGApple, Celgene, others are 'top picks' for spring, Barron's says
In a survey of U.S. money managers, shares of Apple (AAPL), Dow Chemical (DOW), American Airlines (AAL), Celgene (CELG), General Motors (GM), and McDermott (MDR) were identified as top picks for this spring, Barron's contends in its cover story. Reference Link
April 24, 2015
10:59 EDTCELGCelgene call activity attributed to vague takeover speculation
Subscribe for More Information
10:22 EDTCELGRumor: Celgene active on vague takeover speculation
Celgene (CELG) shares are active on speculation Bristol-Myers (BMY) may be interested in acquiring the company.
08:09 EDTBMYBristol-Myers May weekly volatility elevated into Q1 and outlook
Bristol-Myers May weekly call option implied volatility is at 27, May is at 21, June is at 22, September is at 22; compared to its 26-week average of 22 according to Track Data, suggesting large near term price movement into the expected release of Q1 results on April 28.
07:58 EDTMRKMerck May weekly volatility elevated into Q1 and outlook
Subscribe for More Information
07:47 EDTBMYBristol-Myers receives positive CHMP opinion in EU for Opdivo
Subscribe for More Information
07:11 EDTGSKAgenus: GSK's RTS,S vaccine showed statistically significant results in study
Subscribe for More Information
05:39 EDTCELGCelgene announces strategic collaboration with AstraZeneca
Subscribe for More Information
05:35 EDTMRKMerck Phase 3 C-EDGE program shows high sustained virologic responses
Subscribe for More Information
April 23, 2015
17:45 EDTCELGCelgene announces fulfillment of approval requirements for POMALYST
Subscribe for More Information
16:39 EDTMRKACETO subsidiary to launch Timolol Maleate Ophthalmic Solution
Subscribe for More Information
14:20 EDTJNJEarnings Watch: Google up close to 8.5% since last earnings report
Subscribe for More Information
11:02 EDTJNJJohnson & Johnson increases dividend by 7.1% to 75c
Subscribe for More Information
10:02 EDTJNJAbbVie says communication with Johnson & Johnson has been 'very positive'
Subscribe for More Information
09:52 EDTNVSEli Lilly sees at least $200M in savings from Novartis Animal Health acquisition
09:20 EDTCELG, SHPGCelgene patent latest to be challenged by Hayman Capital's Bass
The Coalition For Affordable Drugs, a group linked to Hayman Capital's Kyle Bass, has requested an Inter Partes Review of Claims 1–10 of U.S. Patent No. 6,045,501 held by Celgene (CELG), according to a USPTO filing. The ’501 patent claims methods for delivering a drug, including a teratogenic drug, to a patient while preventing the exposure of a fetus or other contraindicated individuals to the drug. The patent is related to the company's Revlimid drug. BACKGROUND: Previously, the same coalition requested an Inter Partes Review of patents held by Pharmacyclics (PCYC), Acorda Therapeutics (ACOR), Shire (SHPG) and Jazz Pharmaceuticals (JAZZ). On January 7, Reuters reported that Bass planned to take "around 15 pharmaceutical companies with a combined market capitalization of $450B" into an Inter Partes Review for extending patents in questionable ways, citing a presentation made by Bass in Oslo. PRICE ACTION: Shares of Celgene are down 0.5% to $114.92 in pre-market trading.
05:40 EDTMRKMerck announces results from C-SURFER Phase 2/3 study
Subscribe for More Information
05:25 EDTNVSNovartis backs FY15 revenue guidance of growth in mid-single digits
Subscribe for More Information
05:22 EDTNVSNovartis reports Q1 Core EPS $1.33, consensus $1.10
Subscribe for More Information
April 22, 2015
10:02 EDTSNYOn The Fly: Analyst Upgrade Summary
Today's noteworthy upgrades include: Alcatel-Lucent (ALU) upgraded on post-merger outlook at Bernstein... Amazon.com (AMZN) upgraded to Buy, price target raised to $450 at Monness Crespi... BNP Paribas (BNPQY) upgraded to Overweight from Equal Weight at Morgan Stanley... Dolby (DLB) upgraded to Overweight from Neutral at JPMorgan... First Defiance (FDEF) upgraded to Outperform from Market Perform at Raymond James... Gran Tierra (GTE) upgraded to Buy from Neutral at Dundee... Grupo Aval (AVAL) upgraded to Buy from Neutral at Goldman... Manhattan Associates (MANH) upgraded to Buy from Hold at Benchmark Co.... Marriott (MAR) upgraded to Buy from Neutral at MKM Partners... Masco (MAS) upgraded to Outperform from Market Perform at FBR Capital... Nokia (NOK) upgraded on post-merger outlook at Bernstein... Packaging Corp. (PKG) upgraded to Buy from Hold at Deutsche Bank... Rayonier (RYN) upgraded to Sector Perform from Underperform at RBC Capital... Rogers Communications (RCI) upgraded to Buy from Neutral at BofA/Merrill... Sanofi (SNY) upgraded to Neutral from Sell at Citigroup... Select Comfort (SCSS) upgraded to Outperform from Neutral at Wedbush... UniCredit (UNCFF) upgraded to Buy from Sell at Berenberg... Zions Bancorp (ZION) upgraded to Outperform from Market Perform at FBR Capital.
09:26 EDTABTAbbott sees flat growth in Molecular Diagnostics business in Q2
Sees mid-single digit growth for Global Diagnostics growth in Q2. Sees low single digit growth for Global Vascular in Q2. Expects similar double digit growth in EPD in Q2.
09:21 EDTABTAbbott sees FY15 revenue growth to be in low single digits, consensus $20.71B
Subscribe for More Information
09:20 EDTABTAbbott sees Q2 EPS 49c-51c, consensus 52c
Subscribe for More Information
08:18 EDTMRKOrganovo enters into a collaboration agreement with Merck Sharp and Dohme
Subscribe for More Information
07:48 EDTABTAbbott reports Q1 Nutrition sales up 6.3% to $1.67B
Subscribe for More Information
07:46 EDTABTAbbott backs FY15 adjusted EPS $2.10-$2.20, consensus $2.14
Subscribe for More Information
07:45 EDTABTAbbott reports Q1 adjusted EPS 47c, consensus 42c
Subscribe for More Information
07:07 EDTBMY, SNY, SHPGEuropean Association for the Study of the Liver to hold annual meeting
50th Annual Meeting of EASL will be held in Vienna, Austria on April 22-26.
06:52 EDTSNYSanofi upgraded to Neutral from Sell at Citigroup
Subscribe for More Information
April 21, 2015
15:28 EDTABTNotable companies reporting before tomorrow's open
Notable companies reporting before tomorrow's open, with earnings consensus, include Coca-Cola (KO), consensus 42c... Boeing (BA), consensus $1.81... McDonald's (MCD), consensus $1.06... EMC (EMC), consensus 36c... Abbott Laboratories (ABT), consensus 42c... Thermo Fisher Scientific (TMO), consensus $1.61... Bank of New York Mellon (BK), consensus 59c... TE Connectivity (TEL), consensus $1.01... T. Rowe Price Group (TROW), consensus $1.14... St. Jude Medical (STJ), consensus 91c... Amphenol (APH), consensus 56c... Nielsen (NLSN), consensus 47c... Citizens Financial Group (CFG), consensus 34c... Autoliv (ALV), consensus $1.31... D.R. Horton (DHI), consensus 38c... Westinghouse Air Brake Technologies (WAB), consensus 95c... Huntington Bancshares (HBAN), consensus 19c... SEI Investments (SEIC), consensus 49c... AutoNation (AN), consensus 89c... Gentex (GNTX), consensus 25c... Ryder System (R), consensus $1.00... Owens Corning (OC), consensus 13c... NuStar Energy (NS), consensus 58c... Six Flags (SIX), consensus (67c)... Tupperware Brands (TUP), consensus 98c... MarketAxess Holdings (MKTX), consensus 64c... Lithia Motors (LAD), consensus $1.22... Knight Transportation (KNX), consensus 31c... Evercore Partners (EVR), consensus 58c... Potlatch (PCH), consensus 19c... Natus Medical (BABY), consensus 29c... AZZ (AZZ), consensus 59c... United Community Banks (UCBI), consensus 29c... Sonus Networks (SONS), consensus (31c)... Angie's List (ANGI), consensus 0c... Pacific Premier Bancorp (PPBI), consensus 27c.
10:01 EDTPFEPfizer receives FDA breakthrough therapy designation for Xalkori
Subscribe for More Information
10:00 EDTBMYOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
09:01 EDTSNYGenzyme initiates Phase 2a trial to evaluate pharmocodynamics of GZ/SAR402671
Subscribe for More Information
08:30 EDTMRKMerck reaffirms commitment to developing medicines for infectious diseases
Merck reaffirmed its longstanding commitment to discovering and developing novel medicines in the global fight against infectious diseases, including infections caused by resistant bacteria and other pathogens. At this year’s 25th European Congress of Clinical Microbiology and Infectious Diseases, April 25-28 in Copenhagen, Denmark, researchers are scheduled to present more than 30 scientific data presentations on the company’s broad portfolio of marketed and investigational anti-infective medicines. Merck completed its acquisition of Cubist Pharmaceuticals, Inc. on Jan. 21, 2015, and continues to build on both companies’ work in infectious disease. Antimicrobial research remains an important area of focus. In addition to a combined portfolio of antibiotic and antifungal medicines, vaccines, and medicines for HIV and HCV, Merck has multiple programs that span discovery through late-stage development. In total, Merck currently has more than 15 ongoing clinical trials evaluating antibiotic, antifungal and antiviral agents for the prevention and treatment of infectious disease. These trials are projected to enroll approximately 8,000 patients.
08:18 EDTPFEPain Therapeutics resumes responsibility for Remoxy
Subscribe for More Information
08:06 EDTPFEPfizer says Phase 3 inotuzumab ozogamicin study met first primary endpoint
Subscribe for More Information
06:44 EDTBMYBristol-Myers upgraded on early Opdivo success at Morgan Stanley
As previously reported, Morgan Stanley upgraded Bristol-Myers to Overweight from Equal Weight. The firm raised estimates above consensus and increased its price target on the stock to $80 from $60 following confirmation of Opdivo's survival benefits in lung cancer. Morgan Stanley expects Opdivo to be one of the top three pharma-bio launches over the next several years and notes Bristol is ahead of the competition in immuno-oncology combination drug development.
06:15 EDTBMYBristol-Myers upgraded to Overweight from Equal Weight at Morgan Stanley
Subscribe for More Information
05:26 EDTNVSNovartis says data shows Gilenya high efficacy
Novartis announced new analysis from the Phase III FREEDOMS and FREEDOMS II. The data showed that previously-treated patients with highly-active relapsing multiple sclerosis, or RMS, who were treated with Gilenya had a six-times greater likelihood of achieving 'no evidence of disease activity' across four key measures of disease activity compared to placebo over two years. This is referred to as NEDA4 and is achieved when a patient with RMS has no relapses, no new MRI lesions, no MS-related brain shrinkage and no disability progression. This analysis was the first time patients with highly-active RMS who had been treated in the previous year with an injectable therapy were assessed using the NEDA4 definition that includes brain shrinkage. Brain shrinkage is a marker of the widespread inflammatory damage in the central nervous system and is associated with accumulated loss of function. By using this updated NEDA4 definition, physicians are able to get a more complete picture of a patient's disease and response to treatment, which is crucial to identify the optimal therapy to slow short- and long-term disease progression. This is especially important for people with highly-active RMS, who are at a greater risk of relapses and future loss of function, and may therefore require a different treatment approach.
<< 1 | 2 | 3 | 4 | 5 | 6 | 7 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use